GlassScriptPhysician profile
Brooke Bailey Stokes
NPI 1265752778
$4,695.84
in general payments reported to CMS, 2019-2025
29 companies · $846 in 2025
The $846 reported for 2025 was more than what 94% of Obstetrics & Gynecology (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Obstetrics & Gynecology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $743 · 2022: $960 · 2023: $1,367 · 2024: $780 · 2025: $846.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,719 · Education: $274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,718.80 |
| Education | $273.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $862.85 | 2023-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $771.25 | 2021-2025 | |
| Exeltis, USA INC. | $501.29 | 2021-2025 | Slynd, Solosec |
| Evofem Biosciences, INC. | $367.12 | 2021-2025 | Phexxi, Solosec, Phexx |
| Pfizer INC. | $298.23 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $296.35 | 2023-2025 | Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $290.41 | 2021-2025 | |
| Sage Therapeutics, LLC | $191.60 | 2021-2025 | Zurzuvae |
| Shield Therapeutics INC | $158.86 | 2022-2025 | Accrufer |
| Amgen INC. | $155.87 | 2021-2024 | Evenity, Prolia |
| Avion Pharmaceuticals | $133.60 | 2021-2023 | Balcoltra |
| Mayne Pharma Commercial LLC | $95.52 | 2023-2025 | |
| Myovant Sciences INC. | $83.29 | 2021-2022 | |
| Millicent US INC | $56.77 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Supernus Pharmaceuticals, INC. | $53.89 | 2025 | Qelbree |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lupin INC. | $50.01 | 2021 | |
| Therapeuticsmd, INC. | $48.36 | 2021 | |
| Organon LLC | $46.46 | 2022-2023 | Nexplanon |
| Hologic Sales and Service, LLC | $44.87 | 2023-2024 | Novasure, Myosure Tissue Removal Device |
| Scynexis, INC. | $37.40 | 2022 | |
| Welch Allyn | $24.97 | 2021 | |
| Daiichi Sankyo INC. | $23.20 | 2021 | |
| Becton, Dickinson and Company | $21.98 | 2025 | Bd Onclarity |
| Pacira Pharmaceuticals Incorporated | $20.08 | 2024 | Exparel |
| Takeda Pharmaceuticals U.S.A., INC. | $16.60 | 2022 | |
| Novo Nordisk INC | $16.35 | 2024 | Wegovy |
| Medtronic, INC. | $14.22 | 2025 | Ligasure |
| Aspira Women'S Health INC | $11.59 | 2021 | |
| Veracyte, INC. | $2.85 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Stokes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.